Ultra-Low-Dose nivolumab (20 mg, 6% of the FDA-approved flat dose) does the job in Head and Neck Cancer. 1-year OS improved, from 16.3% to 43.4%, HR 0.545; P = .0036. Fantastic trial! De-escalation IO studies are highly needed.
Benjamin Besse
@BenjaminBesseMD
Medical Oncologist- Lung cancer, thymic & NUT carcinomas. Head of Clinical Research @GustaveRoussy, Head of Scientific Chairs Council @EORTC. Tweets are my own.
France
Joined January 2015
